Cargando…
HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients
BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453853/ https://www.ncbi.nlm.nih.gov/pubmed/25077441 http://dx.doi.org/10.1038/bjc.2014.423 |
_version_ | 1782374516472676352 |
---|---|
author | Zhao, X-Y Chang, Y-J Xu, L-P Zhang, X-H Liu, K-Y Li, D Huang, X-J |
author_facet | Zhao, X-Y Chang, Y-J Xu, L-P Zhang, X-H Liu, K-Y Li, D Huang, X-J |
author_sort | Zhao, X-Y |
collection | PubMed |
description | BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typing of the donors in 97 CML patients to address the predictive roles of NK cells in relapse undergoing T-cell-replete haploidentical transplantation. RESULTS: Patients with class I ligands for the donor-inhibitory KIR gene exhibited decreased molecular and haematologic relapse rates (P=0.003 and P=0.015, respectively). There was a significantly reduced risk of molecular and haematologic relapse in patients with HLA-C1C2 or C2C2 who accepted donors with KIR2DS1 or in patients with HLA-Bw4 who accepted donors with KIR3DS1 (‘recipient with relevant KIR ligand for donor-activating KIR', n=25), compared with the remaining transplants (n=72, P=0.009 and P=0.009, respectively). In addition, the presence of class I ligand in the recipients of donor-activating KIR contributed to a decreased relapse rate in patients lacking class I ligand in the recipient of donor-inhibitory KIR (P=0.04 and P=0.03, respectively). CONCLUSIONS: This study suggests that the presence of class I ligands for the donor-activating or donor-inhibitory KIR gene in the recipient might confer some protection against leukaemic relapse in T-cell-replete haploidentical transplantation. |
format | Online Article Text |
id | pubmed-4453853 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-44538532015-09-09 HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients Zhao, X-Y Chang, Y-J Xu, L-P Zhang, X-H Liu, K-Y Li, D Huang, X-J Br J Cancer Clinical Study BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typing of the donors in 97 CML patients to address the predictive roles of NK cells in relapse undergoing T-cell-replete haploidentical transplantation. RESULTS: Patients with class I ligands for the donor-inhibitory KIR gene exhibited decreased molecular and haematologic relapse rates (P=0.003 and P=0.015, respectively). There was a significantly reduced risk of molecular and haematologic relapse in patients with HLA-C1C2 or C2C2 who accepted donors with KIR2DS1 or in patients with HLA-Bw4 who accepted donors with KIR3DS1 (‘recipient with relevant KIR ligand for donor-activating KIR', n=25), compared with the remaining transplants (n=72, P=0.009 and P=0.009, respectively). In addition, the presence of class I ligand in the recipients of donor-activating KIR contributed to a decreased relapse rate in patients lacking class I ligand in the recipient of donor-inhibitory KIR (P=0.04 and P=0.03, respectively). CONCLUSIONS: This study suggests that the presence of class I ligands for the donor-activating or donor-inhibitory KIR gene in the recipient might confer some protection against leukaemic relapse in T-cell-replete haploidentical transplantation. Nature Publishing Group 2014-09-09 2014-07-31 /pmc/articles/PMC4453853/ /pubmed/25077441 http://dx.doi.org/10.1038/bjc.2014.423 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Zhao, X-Y Chang, Y-J Xu, L-P Zhang, X-H Liu, K-Y Li, D Huang, X-J HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title | HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title_full | HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title_fullStr | HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title_full_unstemmed | HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title_short | HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
title_sort | hla and kir genotyping correlates with relapse after t-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453853/ https://www.ncbi.nlm.nih.gov/pubmed/25077441 http://dx.doi.org/10.1038/bjc.2014.423 |
work_keys_str_mv | AT zhaoxy hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT changyj hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT xulp hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT zhangxh hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT liuky hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT lid hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients AT huangxj hlaandkirgenotypingcorrelateswithrelapseaftertcellrepletehaploidenticaltransplantationinchronicmyeloidleukaemiapatients |